Real-Life Effectiveness and Tolerability of Brivaracetam in Focal to Bilateral and Primary Generalized Tonic-Clonic Seizures

Table 4

Treatment-emergent adverse events during follow-up.

	3 months ()	6 months ()	12 months ()	Total ()
Patients reporting TEAEs, (%)	20 (20.6)	12 (14.4)	10 (10.6)	34 (29.8)
Total number of different TEAEs	30	16	15	52
Reported symptoms,(%)
Ataxia	—	—	1 (1.1)	1 (0.9)
Weight gain	—	1 (1)	1 (1.1)	2 (1.8)
Weakness	1 (1)	—	1 (1.1)	1 (0.4)
Drowsiness	10 (10.3)	6 (5.8)	3 (3.2)	17 (14.9)
Dizziness	1 (1)	—	1 (1.1)	2 (1.8)
Irritability	4 (4.1)	—	2 (2.1)	5 (4.4)
Other	9 (9.3)	8 (7.7)	6 (6.4)	16 (14)

TEAEs: treatment-emergent adverse events.